Sullivan RJ - Search Results

1

Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma.

Frankenthaler A, Sullivan RJ, Wang W, Renzi S, Seery V, Lee MY, Atkins MB. Frankenthaler A, et al. Among authors: sullivan rj. Melanoma Res. 2010 Dec;20(6):496-500. doi: 10.1097/CMR.0b013e32833e9f5b. Melanoma Res. 2010. PMID: 20823779

2

Molecular-targeted therapy in malignant melanoma.

Sullivan RJ, Atkins MB. Sullivan RJ, et al. Expert Rev Anticancer Ther. 2009 May;9(5):567-81. doi: 10.1586/era.09.20. Expert Rev Anticancer Ther. 2009. PMID: 19445574 Review.

3

Cytokine therapy in melanoma.

Sullivan RJ, Atkins MB. Sullivan RJ, et al. J Cutan Pathol. 2010 Apr;37 Suppl 1:60-7. doi: 10.1111/j.1600-0560.2010.01507.x. J Cutan Pathol. 2010. PMID: 20482677 Review. No abstract available.

4

An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.

Panka DJ, Sullivan RJ, Mier JW. Panka DJ, et al. Among authors: sullivan rj. Melanoma Res. 2010 Oct;20(5):401-7. doi: 10.1097/CMR.0b013e32833d8d48. Melanoma Res. 2010. PMID: 20679909 Free PMC article.

5

Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.

Sullivan RJ, Atkins MB. Sullivan RJ, et al. Expert Opin Investig Drugs. 2010 Oct;19(10):1205-16. doi: 10.1517/13543784.2010.504709. Expert Opin Investig Drugs. 2010. PMID: 20687784 Review.

6

Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.

DeRose ER, Pleet A, Wang W, Seery VJ, Lee MY, Renzi S, Sullivan RJ, Atkins MB. DeRose ER, et al. Among authors: sullivan rj. Melanoma Res. 2011 Aug;21(4):364-9. doi: 10.1097/CMR.0b013e3283471086. Melanoma Res. 2011. PMID: 21540750 Free PMC article.

7

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. Joseph RW, et al. Among authors: sullivan rj. J Immunother. 2012 Jan;35(1):66-72. doi: 10.1097/CJI.0b013e3182372636. J Immunother. 2012. PMID: 22130161 Free PMC article.

8

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.

Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Joseph RW, et al. Among authors: sullivan rj. J Immunother. 2012 Nov-Dec;35(9):711-5. doi: 10.1097/CJI.0b013e3182742c27. J Immunother. 2012. PMID: 23090080

9

Emerging clinical issues in melanoma in the molecularly targeted era.

Sullivan RJ, Atkins MB. Sullivan RJ, et al. Methods Mol Biol. 2014;1102:11-26. doi: 10.1007/978-1-62703-727-3_2. Methods Mol Biol. 2014. PMID: 24258971 Review.

10

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.

Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ. Ackerman A, et al. Among authors: sullivan rj. Cancer. 2014 Jun 1;120(11):1695-701. doi: 10.1002/cncr.28620. Epub 2014 Feb 27. Cancer. 2014. PMID: 24577748 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

450 results

Search Page

Filters